Personalizing Lipid Management: Statin Treatment Considerations in

Patients With HIV

HIV-AIDS and CHD Risk

MI Rates Are Higher in HIV Patients Than in Uninfected Individuals

Dyslipidemia in HIV

HAART Lipid Effects

HAART Lipid Effects (cont)

Recent FDA Label Changes for Statin Combination Rx With PIs

Switching HAART to Improve Dyslipidemia in Those With HIV

34-Year-Old HIV-Infected Man

34-Year-Old HIV-Infected Man (cont)

34-Year-Old HIV-Infected Man: Medications

The Statin Armamentarium: Individual Metabolism

Characteristics

Coadministering Statins With Protease Inhibitors: Dose Limitations

38-Year-Old HIV-Infected Man

38-Year-Old HIV-Infected Man (cont)

D:A:D Study: Observed and Predicted Rates of MI by Duration of CART in HIV-Infected Patients

Lipid Effects of Different Boosted PI Regimens

STARTMRK: Effect of Raltegravir vs Efavirenz on Lipid Parameters at 96

Weeks

MERIT Substudy: Effect of Maraviroc vs Efavirenz on Lipid

Parameters at 96 Weeks

HIV-Infected Patients Have Elevated Levels of Inflammation

Even With ART

NCEP ATP III LDL-C Goals Are Reasonable in HIV-Infected

Patients

The DAD Study: Risk Factors for MI in HIV-Infected Patients on ART

Smoking Status in Patients With HIV/AIDS

The Statin Class: Approximate LDL-C Lowering Efficacy at Different Doses

In Theory, HAART Interactions With Rosuvastatin Should Be Limited, However…

Statin Dose Limitations in HIV-Infected Patients on Protease Inhibitors

Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-

Accidental Death: ACTG ALLRT Cohort

Program Summary